Acinetobacter Pneumonia: Improving Outcomes With Early Identification and Appropriate Therapy.
Vazquez Guillamet C, Kollef MH.
Clin Infect Dis. 2018 Oct 15;67(9):1455-1462. doi: 10.1093/cid/ciy375.
PMID:29741597
Effect of colistin combined with sulbactam: 9 g versus 12 g per day on mortality in the treatment of carbapenems resistant Acinetobacter baumannii pneumonia: A randomized controlled trial.
Ungthammakhun C, Vasikasin V, Simsiriporn W, Juntanawiwat P, Changpradub D.
Int J Infect Dis. 2024 Dec;149:107267. doi: 10.1016/j.ijid.2024.107267. Epub 2024 Oct 16.
PMID:39423948
Sulbactam-durlobactam for Acinetobacter pneumonia.
Potentially effective antimicrobial treatment for pneumonia caused by isolates of carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii complex species: what can we expect in the future?
Jean SS, Liu CY, Huang TY, Lai CC, Liu IM, Hsieh PC, Hsueh PR.
Expert Rev Anti Infect Ther. 2024 Dec;22(12):1171-1187. doi: 10.1080/14787210.2024.2412637. Epub 2024 Oct 9.